Post Kala-Azar Dermal Leishmaniasis following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) for Primary Visceral Leishmaniasis in Bihar, India

Hdl Handle:
http://hdl.handle.net/10144/311612
Title:
Post Kala-Azar Dermal Leishmaniasis following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) for Primary Visceral Leishmaniasis in Bihar, India
Authors:
Burza, Sakib; Sinha, Prabhat Kumar; Mahajan, Raman; Sanz, Marta González; Lima, María Angeles; Mitra, Gaurab; Verma, Neena; Das, Pradeep
Journal:
PLoS Neglected Tropical Diseases
Abstract:
The skin disorder Post Kala-Azar Dermal Leishmaniasis (PKDL) occurs in up to 10% of patients treated for visceral leishmaniasis (VL) in India. The pathogenesis of PKDL is not yet fully understood. Cases have been reported in India following therapy with most available treatments, but rarely in those treated with liposomal amphotericin B (Ambisome). Between July 2007 and August 2012 with the support of the Rajendra Memorial Research Institute (RMRI), Médecins Sans Frontières (MSF) supported a VL treatment programme in Bihar, India-an area highly endemic for Leishmania donovani-in which 8749 patients received 20 mg/kg intravenous Ambisome as first-line treatment. This study describes the characteristics of patients who returned to the MSF supported treatment programme with PKDL.
Publisher:
Public Library of Science
Issue Date:
Jan-2014
URI:
http://hdl.handle.net/10144/311612
DOI:
10.1371/journal.pntd.0002611
PubMed ID:
24392171
Language:
en
ISSN:
1935-2735
Appears in Collections:
Leishmaniasis/Kala Azar

Full metadata record

DC FieldValue Language
dc.contributor.authorBurza, Sakiben_GB
dc.contributor.authorSinha, Prabhat Kumaren_GB
dc.contributor.authorMahajan, Ramanen_GB
dc.contributor.authorSanz, Marta Gonzálezen_GB
dc.contributor.authorLima, María Angelesen_GB
dc.contributor.authorMitra, Gauraben_GB
dc.contributor.authorVerma, Neenaen_GB
dc.contributor.authorDas, Pradeepen_GB
dc.date.accessioned2014-01-20T21:28:35Z-
dc.date.available2014-01-20T21:28:35Z-
dc.date.issued2014-01-
dc.identifier.citationPost Kala-Azar Dermal Leishmaniasis following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) for Primary Visceral Leishmaniasis in Bihar, India. 2014, 8 (1):e2611 PLoS Negl Trop Disen_GB
dc.identifier.issn1935-2735-
dc.identifier.pmid24392171-
dc.identifier.doi10.1371/journal.pntd.0002611-
dc.identifier.urihttp://hdl.handle.net/10144/311612-
dc.description.abstractThe skin disorder Post Kala-Azar Dermal Leishmaniasis (PKDL) occurs in up to 10% of patients treated for visceral leishmaniasis (VL) in India. The pathogenesis of PKDL is not yet fully understood. Cases have been reported in India following therapy with most available treatments, but rarely in those treated with liposomal amphotericin B (Ambisome). Between July 2007 and August 2012 with the support of the Rajendra Memorial Research Institute (RMRI), Médecins Sans Frontières (MSF) supported a VL treatment programme in Bihar, India-an area highly endemic for Leishmania donovani-in which 8749 patients received 20 mg/kg intravenous Ambisome as first-line treatment. This study describes the characteristics of patients who returned to the MSF supported treatment programme with PKDL.en_GB
dc.language.isoenen
dc.publisherPublic Library of Scienceen_GB
dc.rightsArchived with thanks to PLoS Neglected Tropical Diseasesen_GB
dc.subjectKala Azar/Visceral Leishmaniasisen_GB
dc.titlePost Kala-Azar Dermal Leishmaniasis following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) for Primary Visceral Leishmaniasis in Bihar, Indiaen
dc.identifier.journalPLoS Neglected Tropical Diseasesen_GB

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.